8-K: Acutus Medical Secures Waiver and Amends Credit Agreement Amidst Arbitration

Acutus Medical has amended its credit agreement with Deerfield Partners to waive potential defaults arising from an arbitration demand and modify terms related to a possible Nasdaq delisting.

Summary

• Acutus Medical has entered into an agreement with Deerfield Partners to amend its existing credit agreement.
• The amendment addresses potential defaults triggered by an arbitration demand from Biotronik and VascoMed.
• The lenders have agreed to waive any defaults related to the arbitration.
• The credit agreement was modified to prevent a change of control being triggered by a Nasdaq delisting.
• Exposure exceeding $3 million related to the arbitration is now considered an event of default.
• Lender warrants were amended to remove the repurchase option in the event of a delisting.
• The volatility rate used to calculate the Black-Scholes value of the lender warrants was modified to 200%.
• Acutus Medical's obligation to maintain its Nasdaq listing was removed from the warrant purchase agreement.
• The company paid a $100,000 consent fee to the lenders for the amendments.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges and potential risks for Acutus Medical, including an ongoing arbitration, potential delisting, and increased financial obligations. The need for a waiver and amendments to the credit agreement suggests a weak financial position.

Positives

• The waiver from lenders prevents immediate default due to the arbitration.
• The amendment provides flexibility regarding the company's Nasdaq listing.
• The modification of the lender warrants removes a potential financial burden related to a delisting.

Negatives

• Exposure exceeding $3 million related to the arbitration is now an event of default, increasing financial risk.
• The company had to pay a $100,000 consent fee to the lenders.

Risks

• The ongoing arbitration with Biotronik and VascoMed poses a significant financial risk.
• The company faces potential default if arbitration-related expenses exceed $3 million.
• The removal of the obligation to maintain a Nasdaq listing could indicate a potential delisting.

Future Outlook

The company will need to manage the ongoing arbitration and its financial obligations carefully. The removal of the Nasdaq listing obligation suggests a potential delisting is being considered.

Industry Context

The medical device industry is highly competitive and subject to litigation. This amendment reflects the financial challenges Acutus Medical is facing and the need to manage its debt obligations while dealing with legal disputes.

Comparison to Industry Standards

• Many medical device companies face litigation and financial challenges, but the specific terms of this amendment, such as the removal of the Nasdaq listing obligation, are unusual.
• Comparable companies in the medical device space, such as Boston Scientific or Medtronic, typically have stronger balance sheets and are less likely to face such significant financial constraints.
• The 200% volatility rate for the Black-Scholes calculation is very high, indicating a high level of perceived risk by the lenders.

Legal Proceedings

• Acutus Medical is facing an arbitration demand from Biotronik SE & Co. KG and VascoMed GmbH related to alleged breaches of contractual obligations.

Related Party Transactions

• Andrew ElBardissi, a member of the Board of Directors of Acutus Medical, is a partner in Deerfield Management Company, L.P., the investment manager of the lenders.

Stakeholder Impact

• Shareholders face increased risk due to the ongoing arbitration and potential delisting.
• Creditors are protected by the amended credit agreement, but face increased risk if arbitration costs exceed $3 million.
• Employees may be impacted by the company's financial challenges and potential restructuring.

Next Steps

• Acutus Medical needs to manage the ongoing arbitration with Biotronik and VascoMed.
• The company must monitor its arbitration-related expenses to avoid exceeding the $3 million threshold.
• Acutus Medical needs to consider the implications of the removal of the Nasdaq listing obligation.

Key Dates

Keywords

credit agreement, amendment, waiver, arbitration, default, lender warrants, Nasdaq, delisting, Deerfield Partners, Biotronik, VascoMed